Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia — The PUSH-PATH3 Study

2015 ◽  
Vol 42 (5) ◽  
pp. 866-869 ◽  
Author(s):  
Hong Meng ◽  
Gang Liu ◽  
Jianlong Zhai ◽  
Yuzhi Zhen ◽  
Qingzhen Zhao ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Uric Acid ◽  
Serum Creatinine ◽  
Serum Uric Acid ◽  
Clinical Status ◽  
Safety And Efficacy ◽  
Symptomatic Heart Failure ◽  
Heart Failure Patients ◽  
Short Time

Objective.To determine the safety and efficacy of prednisone in patients with symptomatic heart failure (HF) and hyperuricemia.Methods.Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl).Results.Prednisone significantly reduced serum uric acid by 2.99 mg/dl (p < 0.01) and serum creatinine by 0.17 mg/dl (p < 0.01). These favorable effects were associated with a remarkable increase in urine output, improvement in renal function, and improvement in clinical status.Conclusion.Prednisone can be used safely in symptomatic HF patients with hyperuricemia.

Association of Serum Renal Function Levels with Heart Failure Disease in Iraqi Patients

2021 ◽  
pp. 2464-2466
Author(s):  
Jinan Hussein Murtadha ◽  
Iman Hashim Abdul Razzaq
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Failure Group ◽  
Heart Failure Patients ◽  
Group 2 ◽  
Renal Function Tests ◽  
Effect Of Age ◽  
Group 1

Renal function tests are commonly used in clinical practice to look for renal disease, the most common includes the serum urea, uric acid and creatinine. Heart failure patients have a higher incidence of renal function test abnormalities than individuals who do not have heart failure disease. Fifty subjects of adults (male) were divided in to two groups, 25 subjects (healthy) as control (group1) and 25 subjects with heart failure (group 2). Our results indicate that serum uric acid, urea, and creatinine values were significantly elevated (P≤0.05) in patients group (2) compared with healthy group (1). The results also showed, the effect of age categories on uric acid blood urea nitrogen and creatinine values (P≤0.05) and there were no significant differences between age (41-60) years and (61-80) years. This study also shows a strong correlation between serum uric acid, urea and creatinine values (P≤0.05) in heart failure patients. Conclusion: It concluded from the above finding that there was effect of heart failure disease on renal function levels.

scholarly journals Correlation of serum uric acid with renal function parameters in preeclampsia.

2020 ◽  
Vol 27 (12) ◽  
pp. 2703-2707
Author(s):  
Muddasir Zia ◽  
Rukhshan Khurshid ◽  
Uzma Jabbar ◽  
Adnan Riaz ◽  
Roohi Jabbar ◽  
...  
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Serum Creatinine ◽  
Serum Uric Acid ◽  
Cross Sectional Study ◽  
Urinary Protein ◽  
Estimation Of Parameters ◽  
Cross Sectional ◽  
Significant Difference ◽  
Relationship Of

Objectives: Study was designed to find out the Correlation of serum uric acid with renal function parameters in Preeclampsia. Study Design: Cross Sectional study. Setting: Sir Ganga Ram Hospital Lahore. Period: July 2016 to July 2017. Material & Methods: Level of serum uric acid, serum creatinine and blood urea of 40 Preeclamptic women and 30 gestation-matched normotensive controls were estimated. Their Demographic and clinical characteristics were noted. The blood sample was analyzed for biochemical parameters, blood urea, serum uric acid, serum creatinine and urinary protein. Result: Mean age and gestational age of women was 25 weeks with BMI 29 Kg/m2. Level of serum uric acid and blood urea and serum creatinine were increased, but significant difference only observed with serum uric acid and blood urea with marked proteinuria. An inverse relationship of serum uric acid with urinary protein was observed. A direct relationship, of serum uric acid with serum creatinine was observed. Conclusion: it is concluded that estimation of parameters of renal function of preeclamptic women are important along with hyperuicaemia.

Comparison of Allopurinol And Febuxostat in Asymptomatic Hyperuricemic Patients and their Impact on Serum Creatinine

2019 ◽  
Vol 10 (1) ◽  
pp. 17-21
Author(s):  
Tafazzul Hussain ◽  
Musarrat Sultana ◽  
Syeda Amber Zaidi ◽  
Syed Saud Hasan ◽  
Mohsin Turab ◽  
...  
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Serum Creatinine ◽  
Serum Uric Acid ◽  
Blood Parameters ◽  
Mean Difference ◽  
P Value ◽  
Baseline Serum ◽  
Group A ◽  
Group B

Objective: To determine the effect of Allopurinol & Febuxostat for the treatment of hyperuricemic patients & its influence on renal function by measuring serum creatinine level. Study Design & setting: The clinical trial was conducted at Dr. Ruth K M Pfau Civil Hospital, Karachi, during the period of September 2018 to March 2019 Methodology: 60 patients with sUA > 6.8 mg/dl were registered. A detailed history was taken, patient's baseline serum Uric Acid (sUA) & serum Creatinine were measured. Patients were divided into two groups to receive Allopurinol, 300 mg & Febuxostat 80 mg, daily for 90-days. The blood parameters were repeated at day 30 and 90. Results: Group-A (Allopurinol treated patients) baseline uric acid changed from mean 8.79 ± 0.98 mg/dl to 6.40 ± 0.86 mg/dl at day 90. In Group-B (Febuxostat treated patients) sUA baseline mean changed from 8.85 ± 0.97 mg/dl to 5.96 ± 0.68 mg/dl. Mean difference ± SD change of serum uric acid in Group-A was 2.39 ± 1.15 mg/dl and with Group-B it was 2.90 ± 0.87 mg/dl. Mean Serum Creatinine in Group-A changed from 1.54 ± 0.39 mg/dl to mean 1.48 ± 0.40 mg/dl compared with Group-B where it changed from 1.42 ± 0.30 mg/dl to 1.45 ± 0.31 mg/dl at day-90. Mean difference ± SD of serum Creatinine in Group-A was 0.11 ± 0.25 mg/dl & in Group-B it was, 0.03 ± 0.15 mg/dl. The above changes were statistically non-significant with p-value of 0.144. Conclusion: Allopurinol and Febuxostat treatment resulted in improvement of serum Uric Acid levels while maintaining their renal function

scholarly journals Serum Uric Acid Predicts Declining of Circulating Proangiogenic Mononuclear Progenitor Cells in Chronic Heart Failure Patients

2014 ◽  
Vol 6 (3) ◽  
pp. 153-162 ◽  
Author(s):  
Alexander E. Berezin ◽  
Alexander A. Kremzer ◽  
Tatyana A. Samura ◽  
Tatyana A. Berezina ◽  
Yulia V. Martovitskaya
Keyword(s):  
Heart Failure ◽  
Uric Acid ◽  
Chronic Heart Failure ◽  
Progenitor Cells ◽  
Serum Uric Acid ◽  
Heart Failure Patients

Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) Study

2013 ◽  
Vol 29 (9) ◽  
pp. 1048-1054 ◽  
Author(s):  
Chao Liu ◽  
Qingzhen Zhao ◽  
Yuzhi Zhen ◽  
Yanqiu Gao ◽  
Li Tian ◽  
...  
Keyword(s):  
Heart Failure ◽  
Uric Acid ◽  
Symptomatic Heart Failure ◽  
Heart Failure Patients

scholarly journals Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid

2020 ◽  
Vol 27 (2_suppl) ◽  
pp. 35-45
Author(s):  
Andrea Tedeschi ◽  
Piergiuseppe Agostoni ◽  
Beatrice Pezzuto ◽  
Ugo Corra’ ◽  
Domenico Scrutinio ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Chronic Heart Failure ◽  
Kidney Disease ◽  
Serum Uric Acid ◽  
Elevated Serum ◽  
Morbidity And Mortality ◽  
Heart Failure Patients ◽  
Increased Risk

Despite improvements in pharmacotherapy, morbidity and mortality rates in community-based populations with chronic heart failure still remain high. The increase in medical complexity among patients with heart failure may be reflected by an increase in concomitant non-cardiovascular comorbidities, which are recognized as independent prognostic factors in this population. Heart failure and chronic kidney disease share many risk factors, and often coexist. The presence of kidney failure is associated with incremented risk of cardiovascular and non-cardiovascular mortality in heart failure patients. Chronic kidney disease is also linked with underutilization of evidence-based heart failure therapy that may reduce morbidity and mortality. More targeted therapies would be important to improve the prognosis of patients with these diseases. In recent years, serum uric acid as a determinant of cardiovascular risk has gained interest. Epidemiological, experimental and clinical data show that patients with hyperuricaemia are at increased risk of cardiac, renal and vascular damage and cardiovascular events. Moreover, elevated serum uric acid predicts worse outcome in both acute and chronic heart failure. While studies have raised the possibility of preventing heart failure through the use of uric acid lowering agents, the literature is still inconclusive on whether the reduction in uric acid will result in a measurable clinical benefit. Available evidences suggest that chronic kidney disease and elevated uric acid could worsen heart failure patients’ prognosis. The aim of this review is to analyse a possible utilization of these comorbidities in risk stratification and as a therapeutic target to get a prognostic improvement in heart failure patients.

scholarly journals Serum uric acid as an index of impaired renal function in congestive heart failure

2012 ◽  
Vol 9 (2) ◽  
pp. 137-142 ◽  
Author(s):  
Tian Yu ◽  
Chen Ying ◽  
Deng Bao ◽  
Liu Gang ◽  
Ji Zhen-Guo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Impaired Renal Function
Sign in / Sign up

Export Citation Format

Share Document